Tirzepatide
Overview
Research-use dual GLP-1/GIP receptor agonist supplied for studies of incretin signaling, glucose-regulation pathways, and energy-balance models.
- Concentration
- 10 mg
- Stock
- In stock
Product details
Tirzepatide is a synthetic dual GLP-1/GIP receptor agonist used in research models of incretin signaling and metabolic pathway biology. Pattern lists this material for controlled laboratory research.
Research Targets: GLP-1 receptor signaling, GIP receptor signaling, pancreatic and metabolic pathway models.
Key Feature: Dual incretin receptor agonist research peptide with fatty diacid design element.
Research Focus Areas: Incretin synergy, glucose-regulation pathway models, energy-balance signaling, pancreatic function studies.
Common Models: Rodent metabolic models, pancreatic function assays, receptor-signaling systems.
Mechanistic Interests: Dual receptor engagement, insulin secretion markers, cAMP pathway dynamics, metabolic hormone crosstalk.
Use Boundary: Research use only; not for human or veterinary use; no diagnostic, therapeutic, or consumption use is implied.
Research context
Peptide guide
Open full guide- Guide profile
- Dual GIP/GLP-1 Receptor Agonist
- Composition
- Synthetic polypeptide and first-in-class dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
- Discovery
- Developed by Eli Lilly to combine GIP and GLP-1 receptor activity in a single incretin-based therapy.
- Research scope
- Large Phase 3 programs SURPASS (diabetes) and SURMOUNT (obesity/weight management) demonstrated clinically meaningful glycemic and weight outcomes
- Regulatory status
- FDA-approved for type 2 diabetes, chronic weight management, and OSA in obesity; other uses (e.g., NAFLD, PCOS) remain off-label or investigational
Safety context
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Hypersensitivity to tirzepatide or any component
Research-use notice: Tirzepatide has strong clinical evidence for approved type 2 diabetes, chronic weight-management, and OSA-in-obesity indications. Claims outside those labels require indication-specific evidence review. Compounded or research-market formulations lack the same regulatory oversight as approved products.
Full guide includes 10 reference entries.
One kit adds 10 vials to WooCommerce checkout.